A regenerative medicine company

Established to transform innovative concepts into cutting edge wound care therapies.

Our patented manufacturing process

Delicately preserves biological materials and produce highly standardised multi-plattform regenerative products that are easy to ship, use and store.

An innovative human amnion-derived regenerative therapy that is ready to use, ‘off the shelf’

Bespoke application

Delivering Omnigen regeneration in the clinic, without the need of surgery.

A complementary tissue service

Providing clinical centres with improved access to Omnigen, whilst avoiding risk of wasting surplus tissue and money.

A regenerative medicine company

Amniotic membrane derived dry matrix (human)

Bespoke contact lens application of Omnigen

Storage to provide Omnigen access when you need it

Creating uniform wound margins for easier application

Developing high quality and affordable wound care regenerative therapies

Latest News

NuVision form new sales team lead by Jonathan Hamill-Keays

This year has so far consisted of a number of significant additions to the NuVision team. This month, we are delighted to announce the appointment of our new Sales and Marketing Director, Jonathan Hamill-Keays, who will lead and work alongside our new Territory...

NuVision appoints Roger Teasdale as an Independent Non-Executive Director

NuVision Biotherapies is delighted to announce that Roger Teasdale has joined the Board as an Independent Non-Executive Director. Roger enjoyed a successful 25 year career at Smith & Nephew, the FTSE 100 Medical device business focused on the Advanced Wound...

NuVision appoints new chairman – Dr Mark Treherne  

NuVision Biotherapies is delighted to announce the appointment of its new chairman, Dr Mark Treherne. Mark has a PhD in Pharmacology from Cambridge University along with over 25 years of industrial R&D experience in the discovery and development of novel...

Click to follow

Interested in purchasing?

Register your interest